Patent: 9,181,162

Summary for Patent: 9,181,162

Title:	Compositions and methods for glucose transport inhibition
Abstract:	Glucose deprivation is an attractive strategy in cancer research and treatment. Cancer cells upregulate glucose uptake and metabolism for maintaining accelerated growth and proliferation rates. Specifically blocking these processes is likely to provide new insights to the role of glucose transport and metabolism in tumorigenesis, as well as in apoptosis. As solid tumors outgrow the surrounding vasculature, they encounter microenvironments with a limited supply of nutrients leading to a glucose deprived environment in some regions of the tumor. Cancer cells living in the glucose deprived environment undergo changes to prevent glucose deprivation-induced apoptosis. Knowing how cancer cells evade apoptosis induction is also likely to yield valuable information and knowledge of how to overcome the resistance to apoptosis induction in cancer cells. Disclosed herein are novel anticancer compounds that inhibit basal glucose transport, resulting in tumor suppression and new methods for the study of glucose deprivation in animal cancer research.
Inventor(s):	Chen; Xiaozhuo (Athens, OH), Bergmeier; Stephen (Athens, OH)
Assignee:	Ohio University (Athens, OH)
Application Number:	13/071,386
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,181,162
Patent Claims:	see list of patent claims

Details for Patent 9,181,162

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Clinigen, Inc.	PROLEUKIN	aldesleukin	For Injection	103293	05/05/1992		2030-03-24
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	02/20/1991		2030-03-24
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	06/28/2000		2030-03-24
Servier Pharmaceuticals Llc	ONCASPAR	pegaspargase	Injection	103411	02/01/1994		2030-03-24